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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:
• To synthesize qualitative research evidence about community experience with, and understanding and perception of, MDA programmes
for filariasis
• To explore whether programme design and delivery influence the community experience identified in the analysis
We have intentionally kept the objectives broad, and we may modify them as we learn more from our analysis of the included studies, as
is appropriate in qualitative research.
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B A C K G R O U N D
Description of the topic
Lymphatic filariasis (LF) is one of the neglected tropical diseases
(NTDs), which are communicable diseases endemic to tropical and
subtropical countries that cause considerable ill health, particularly
among the poor (Molyneux 2013). The World Health Organization
(WHO) recommends mass drug administration (MDA) to control
all five of the most common NTDs: LF, onchocerciasis, soil-
transmitted helminths, schistosomiasis, and trachoma (Webster
2014). Symptomatic chronic filarial infection causes limb and
genital swelling, peeling of the skin, and fevers. Without treatment,
the infection persists, and without early treatment, some of the
eFects are irreversible and can cause substantive morbidity and
disability in adults who are infected (WHO 2019).
LF occurs in clearly geographically defined areas of the tropics
and is transmitted by a variety of mosquito species, mainly
species of the genus Anopheles or Culex. Repeated exposure to
the bite of infected mosquitoes is required to infect people; hence
vector control is an important preventive measure (WHO 2019).
A variety of highly eFective drugs are available for treatment,
including diethylcarbamazine (DEC), ivermectin, and albendazole
(WHO 2019), although debate surrounds the size of the eFects seen
with albendazole (Macfarlane 2019a).
Apart from vector control, the main tool for eliminating
transmission of the disease is treatment of the disease through
suppression of microfilaraemia with drugs known to be eFective
as tablets, or sometimes with medicated salt (Adinarayanan 2007).
This suppression needs to be done for the whole population over
long periods of time, and MDA to treat the whole population every
year is the approach used most oJen (WHO 2019). In 2018, 893
million people required MDA to stop the spread of infection (WHO
2019).
The 2000 WHO global programme to eliminate lymphatic filariasis
(GPELF) has been important and is ongoing; in addition, more
integrative attempts are being made to treat multiple diseases
through MDA programmes in which several drugs are given
together to combat LF, soil-transmitted helminths, schistosomiasis,
onchocerciasis, and trachoma (Webster 2014). Although it is clear
that MDA if given properly really does help to reduce transmission,
as anticipated some diFiculties are involved in delivering at a local
level (Parker 2013). Some researchers believe the large financial
inputs (valued at USD 2 billion and USD 3 billion annually - Webster
2014) may inadvertently create pressure to highlight programme
success without acknowledging these diFiculties (Parker 2013).
Benefit in controlling these diseases is important because they
aFlict already poor and disadvantaged groups (Molyneux 2013);
the size of the control programmes is considerable. By 2015,
governments and donors had distributed over 6.7 billion tablets
for treatment of LF alone (Specht 2019). However, to deliver
medication on such a scale is a huge logistical task involving co-
ordination between multiple sectors (Gyapong 2018). At the local
level, village volunteers conduct house-to-house visits to identify,
record, and inform the eligible population; this is followed by
fixed day distribution (Allen 2011). Volunteers visit villages over a
large geographical distance aJer completing a normal day's work.
The work is unpaid and may have to be repeated if people were
not at home for the first planned visit (Allen 2011). This can lead
to shortcuts, with some distributors opting to give the tablets
to one family member without ensuring that the entire family
ingest them (Babu 2014). Finally, regular delivery of medicines
assumes that people adhere to treatment. Although providers
have the intention of doing public good, this does not always
mean that communities are willing to take the drugs (Allen 2011).
Problems with adherence have been reported in the literature,
particularly regarding adverse eFects (AEs) (Cabral 2017). Among
people with active infection, AEs are common with treatment. The
death of filarial parasites can cause a local inflammatory response;
so when filarial load is high or worms are killed too rapidly,
drug administration oJen leads to AEs (Kafle 2011). Mild reactions
include fever and nausea, and serious AEs are those that lead to
life-threatening or incapacitating conditions and hospitalization
(Lima 2012). With MDA, it is not clear whether these AEs are
common, as reporting and reporting accuracy are variable (Lima
2012; Wamae 2011; Weerasooriya 1998; WHO 2003). Although the
uninfected population does not experience AEs, those who are
infected may, and this could interfere with subsequent adherence
to drug treatment, although these may not be important barriers to
programmes providing MDA for LF (Mishra 2019)
How the intervention might work
In terms of drug eFects, LF is treated with a two-drug combination
consisting of albendazole and diethylcarbamazine, albendazole
and ivermectin, or ivermectin and diethylcarbamazine. These
treatments reduce microfilarial levels in the infected individual,
and in some cases completely clear infection (Ismail 2001). When
given to whole populations repeatedly over several years, MDA can
reduce filaria levels to the point where transmission can no longer
be sustained (Gyapong 2018). For this reason, the WHO currently
recommends that at least 65% of the population should receive
MDA for at least five years to achieve elimination (WHO 2019). When
applying this strategy, 14 countries have been declared free of LF
(Fang 2019).
In terms of delivery of the drug, MDA itself simply means giving the
drug to whole populations, but this is a general term for a process
that can take a variously organized and managed approach,
with the various approaches themselves likely to influence the
eFectiveness of delivery. For example, MDA can be delivered
by government health staF or by community health workers or
through schools; it can be provided through mobile camps or by
door-to-door visiting; the procedure may include careful household
mapping and adherence recording, or very little attempt may be
made to monitor actual ingestion.
Delivery may take place alongside health education or sensitization
initiatives such as media campaigns or public activities, whereby
people are given information on the purpose of MDA along
with possible opportunities to raise concerns or queries. In
addition, the whole process of planning MDA can vary from
imposed programmes to full "collaborative" projects between
external agencies and the community (Table 1). These programmes
can be organised into top-down, bottom-up, and collaborative
approaches, whereby the latter two have equal or majority
contribution and governance from the communities intended to
benefit (Whitehead 2002). Community involvement in planning
and implementing interventions is thought to generate respect,
trust, and sustainable support for the programme (Leise 2010),
thereby facilitating community participation and engagement
(Annamalai 2016). On the other hand, some point out that top-
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down approaches may be met with limited participation and
missed opportunities to respond to problems arising at the local
level (Silumbwe 2019; Sturmberg 2017), but these approaches may
be simpler and more practical on a large scale. A recent analysis
of top-down and bottom-up approaches to water, electricity, and
sanitation initiatives suggests that in areas with weak economies,
governance, and existing infrastructure, bottom-up approaches
may be less eFective and may require continued support from
external actors (Annamalai 2016).
The way programmes are designed and delivered is likely to
influence how people experience and perceive MDA. Therefore,
in this review, we will carefully describe MDA programmes
from all available data provided by the qualitative studies
included, and in the analysis, we will explore how design
influences community responses. We had considered exploring this
relationship through qualitative comparative analysis, whereby
quantitative and qualitative data are combined in a matrix to
explore their relationship (Candy 2011). However, we intend to
simply synthesize what people think of MDA and not necessarily
identify how acceptability or compliance may be influenced. In
addition, quantitative reviews of eFectiveness that would be
suitable to compare with this study are insuFicient.
How this review might inform or supplement what is
already known in this area
The Cochrane Database of Systematic Reviews includes two
reviews regarding specific treatment regimens of MDA for LF. The
first - Macfarlane 2019a - investigates the eFicacy of albendazole,
given alone or in combination; and the second - Adinarayanan
2007 - investigates the eFicacy of DEC salt. This Cochrane Review
will build on this by exploring how people experience these
programmes but is not specifically linked to either of these
Cochrane Reviews (Adinarayanan 2007; Macfarlane 2019a).
Before starting this review, we sought to examine the questions
addressed, the studies included, and the conclusions drawn from
similar reviews that explored community views and responses to
LF mass treatment programmes. We identified three systematic
reviews and one rapid review that synthesized evidence regarding
delivery and adherence (Table 2). Two reviews collated evidence
globally - one from India and another from sub-Saharan Africa.
Data were collected from studies published up until 2012 (Krentel
2013), 2013 (Babu 2014), 2016 (Silumbwe 2017), or 2017 (Ames
2019). One quantitative and two mixed-methods studies largely
based their findings on quantitative study designs, such as
standardized surveys, which are poorly designed to capture two
types of information: the first, unexpected or novel information
as responses are predetermined; and the second, deeper levels of
reasoning that highlight important beliefs or experiences that fuel
such assertions. Boyd 2010 documents the challenges encountered
by researchers when using the quantitative survey method; the
response they most frequently received was ‘don't know’, and
trial authors questioned whether this was proxy for ‘don't care’,
or if another factor was present that was not being captured
by the research. One mixed-methods study - Krentel 2013 -
supplemented study findings with informal interviews with five
senior LF scientists, although the relationships of these scientists
to MDA programmes and their risk of bias were not disclosed.
This generated some interesting observations on behaviour at the
ground level. A final article - a rapid review commissioned by the
WHO (Ames 2019) - was conducted in part by researchers who have
produced pieces of research advocating for MDA programmes (King
2011). Due to the nature of rapid reviews, limited time may have
been provided to develop theory from the themes identified.
Facilitators outlined in the above studies include training (Ames
2019; Silumbwe 2017), community awareness (Silumbwe 2017),
management of adverse eFects (Ames 2019; Krentel 2013;
Silumbwe 2017), trust (Ames 2019; Krentel 2013), community
involvement in planning and conducting the MDA (Ames 2019), and
whether timing was convenient (Ames 2019). Barriers include fear
of adverse eFects (Babu 2014; Krentel 2013), lack of perception
of benefit (Babu 2014; Krentel 2013), lack of information or
understanding (Ames 2019; Babu 2014; Krentel 2013), delays in
drug delivery (Krentel 2013; Silumbwe 2017), lack of motivation of
distributors (Krentel 2013), and inadequate numbers of distributors
(Ames 2019). Silumbwe 2017 noted some interesting contextual
factors influencing compliance, including the belief that MDA
transmits Ebola, and the thought that MDA is not a priority during
other outbreaks. This may suggest that it is useful to consider
findings in terms of country and context.
The conceptual model was developed in light of the findings
of these reviews and represents current understanding of the
factors that influence adherence at the community level (Figure
1). The diagram aims to help us delineate our thinking before
conducting the review, reading previous reviews, and exploring our
own thoughts. The conceptual model is a guide that is likely to be
revised in light of the findings of this review.
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Figure 1.   Conceptual model of the driving and restraining influences on MDA delivery and adherence.
 
Why is it important to do this review?
Cochrane Reviews conducted previously have helped by listing
barriers to and facilitators of adherence. Decisions to adhere to
treatment are complicated, however, and oJen are related to
multiple competing beliefs and values and the wider socio-political
context. Therefore, we plan to conduct a careful analysis using
recent methods in quality evidence synthesis (QES) (1) to further
examine the context in which these drugs are delivered in an
eFort to explain when sometimes adherence is not as high, as is
desired by policy-makers, and (2) to delineate community views to
provide feedback on programme design. This approach provides
the underpinning for this review, in which we aim to synthesize the
perceptions and experiences of those receiving MDA with the goal
of attaining a broader understanding of the impact of programmes
and consumers' openness towards them.
O B J E C T I V E S
• To synthesize qualitative research evidence about community
experience with, and understanding and perception of, MDA
programmes for filariasis
• To explore whether programme design and delivery influence
the community experience identified in the analysis
We have intentionally kept the objectives broad, and we may
modify them as we learn more from our analysis of the included
studies, as is appropriate in qualitative research.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review will synthesize qualitative research including
ethnographies, phenomenologies, qualitative process evaluations,
and case studies. We define qualitative research as studies that
collect data from ethnographic observations, in-depth interviews,
focus group discussions, and open-ended survey questions.
Appropriate analysis methods for qualitative research include
thematic analysis, narrative analysis, framework analysis, and
grounded theory (Thomas 2008).
We will include mixed-methods studies when it is possible to extract
qualitative data.
We will not include studies that include qualitative data collection
methods but report and analyse all data quantitatively.
We will restrict included studies to those from 2000 to present day,
as this marks the date of the introduction of the Global Programme
for the Elimination of Lymphatic Filariasis and the date that MDA
activities were introduced and scaled up for filariasis (WHO 2019).
We will include both published and unpublished studies.
Topics of interest
• Phenomenon of interest: this review will consider
community experiences, perceptions, or attitudes towards MDA
programmes for LF
• Setting: we will include any setting in which MDA for filariasis
was provided, as the purpose of synthesis to inform decision-
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making is to yield theories that are more transferable and
socially relevant over a broader range of contexts
• Perspectives: we will include the perspectives of any
community member eligible for the MDA programme and village
leaders. Perceptions of lay healthcare workers (those without
formal training or qualifications, including community health
workers and drug distributors as defined by Lewin 2010) and
government health workers may be included to triangulate
results but will be clearly separated from the perspectives
of the general consumer population. The literature on MDA
policies and their implementation is extensive. This review
is not concerned with understanding of policies by those
implementing them; we do not therefore intend to summarize
the views of those aFiliated with the programme design or with
programme governance
• Intervention: we will examine delivery of MDA, which, for
this review, is defined as administration of an antifilarial drug
to the entire at-risk population (irrespective of symptoms or
infection) on a regular, oJen annual, basis. During scoping,
it was identified that most of the available research related
to compliance in MDA programmes focused on LF specifically.
Therefore, this review will focus on community perceptions
towards MDA programmes for LF
Search methods for identification of studies
We developed the search strategy in consultation with Cochrane
EFective Practice and Organisation of Care (EPOC) Information
Specialists.
Electronic searches
We will attempt to identify all relevant studies regardless of
publication status (i.e. published, unpublished, in press, or in
progress). We will search the following databases using the search
terms and strategy described in Table 3 - Cochrane Infectious
Diseases Group Specialized Register; MEDLINE (PubMed); Embase
(OVID); Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library; Latin American and Caribbean
Health Sciences Literature (LILACS (BIREME)); Cumulative Index to
Nursing and Allied Health Literature (CINAHL (EBSCOHost)); Global
Health; CAB Direct; and Science Citation Index - Expanded (all in the
Web of Science). We will limit our searches from publication year
2000 onwards and to studies conducted in English.
We will also search the WHO International Clinical Trials
Registry Platform (www.who.int/ictrp/search/), along with
ClinicalTrials.gov, to identify ongoing trials, using the terms
'filariasis' and 'mass drug administration'.
Searching other resources
The Cochrane Qualitative and Implementation Methods Group
recommends supplementary searching activities due to the limited
availability of qualitative research. To achieve this, we will scan
reference lists and perform citation searching of included studies
and existing reviews identified in the Background. We will contact
experts in the field to ask what they know about published and
unpublished data.
Grey literature
We will search OpenGrey to identify grey literature
(www.opengrey.eu).
Selection of studies
We will import all search results into EndNote, and will remove
any duplicates. Two review authors (MT and Rebecca Thomas
(RT)) will independently screen retrieved search results against the
inclusion criteria. This two-step process will consist of screening
first titles/abstracts, then full text. Using two review authors to
screen is valuable in providing opportunities to explore relevance
and meaning of study findings rather than to reach consensus
(Soilemezi 2018). We will summarize this process in a PRISMA flow
diagram detailing the numbers of studies removed and kept at each
step. We will note the reasons for exclusion of full-text studies and
will present this information in the supplementary material.
Language translation
Due to time and resource demands of translation, only studies
available in English will be eligible for inclusion.
Sampling of studies
The previous version of this review - an unpublished masters
dissertation (Taylor 2019) - returned only 14 studies, and a
subsequent scoping search has not returned any additional studies.
Therefore, we are not expecting to require a sampling strategy.
Data extraction and management
One review author (MT) will independently extract study data using
a predefined data extraction form, which will include information
such as study author, country, study aim, study participants, study
methods, qualitative data collection methods, key study findings,
conceptual models used, programme organization, community
engagement, drug regimen, and rounds of MDA received at the time
of the study.
Assessing the methodological limitations of included
studies
We will assess quality by using a standardized set of criteria to
impart some objective distance and to ensure consistency. We
chose a modified version of the tool developed by the EPPI-centre
for its clear and straightforward approach and use in a similar QES
investigating consumer perceptions and experiences of a health
intervention (Appendix 1; Eshun-Wilson 2019). This tool assessed
the following criteria: rigour in sampling, rigour in data collection,
rigour in analysis, grounding of data, and breadth and depth of
study findings. Each criterion oFered several prompts to aid the
user in making a judgement. For each category, studies received
a score of (1) Yes, a fairly thorough attempt was made, (2) Yes,
several steps were taken, (3) Yes, a few steps were taken, or (4)
No, not at all/not stated/can’t tell. Two review authors (MT and
RT) will independently conduct a quality assessment of each paper
before comparing findings. We will discuss disagreements, and if
consensus cannot be reached, we will consult a third review author.
We will not exclude studies based on our assessment of
methodological limitations. However, we will use information
about methodological limitations to assess our confidence in the
review findings.
Data management, analysis, and synthesis
We will use thematic synthesis as described in Thomas 2008 and
informed by the Braun 2006 thematic analysis. Thematic synthesis
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assumes that knowledge of reality is mediated by perceptions
and beliefs, thus making it an appropriate choice for a study
investigating perceptions, experiences, and acceptability of a
health intervention. This method also assumes that findings are
reproducible and transferable, which aligns with the second study
objective - to explore implications for programme delivery. The
steps to be taken are outlined below.
• Familiarising yourself with the data: review authors (MT and RT)
will read through relevant background literature and the full
length of studies included in the review to become familiar with
and immersed in the data, noting any initial thoughts.
• Generating initial codes: working independently, review authors
(MT and RT) will begin substantive coding, by determining
which segments of text will be assigned simple codes that
reflect their contents rather than researchers’ preconceptions.
This will include both first- and second-order data, with first-
order data being the original quotations, and second order data
comprising study authors' interpretations. EForts will be made
to retain accounts that diFer from the emerging understanding
of the situation. Review authors will then compare individual
codes on a study-by-study basis to reach consensus on the
appropriateness and terminology of each code. The result of this
process will be the development of a shared coding framework
that can be applied to subsequent papers, which may be refined
and amended as new codes emerge.
Description of delivery
In addition, we will attempt to code for aspects of the delivery
system that may have contributed to the emerging perceptions and
acceptability of those receiving MDA. These will include:
• who delivers: community health workers, government health
staF, or teachers;
• how delivered: through schools, through mobile camps, by
door-to-door visiting, by using household mapping;
• adherence monitoring: systems of adherence recording in
place or no such systems; and
• health education and sensitization: with or without
concurrent health education or sensitization initiatives such as
media campaigns or public activities.
Community engagement
We will try to categorize using the seven delivery methods outlined
in Whitehead 2002, or at least by grouping these into three
categories: top-down, bottom-up, and collaborative. When this
information is not available from the report, we will seek other
documents related to MDA policies in the country at the time to
try to input some basic characteristics of the programme, and
we will note that the characteristics are secondarily derived from
other sources. To find this information, we first will screen citations
of the target study, then will refer to policy documents including
Macfarlane 2019b, and finally will perform a Google search for other
documents that refer to these programmes.
Thematic methods
• Searching for themes: working together, we will group codes
into potential themes, gathering all data relevant to each theme.
Here, review authors will interpret meaning behind the data and
will think about the relationships between codes, themes, and
hierarchies of themes. MT, RT, and PG will hold regular meetings
to reflect on emerging themes.
• Reviewing themes: review authors will ensure that the pattern
of data within themes is coherent, and that there is a clear
distinction between themes and subthemes. This may involve
breaking, merging, or removing themes with too little, too much,
or disparate information. We will review included studies a
second time to capture any data missed for newly emerging
themes.
• Defining and naming themes: we will refine the overall story and
terminology of each theme.
Team roles
Producing the report
One review author (MT) will produce a narrative of findings for
each theme, integrating illustrative quotes that are vivid and lack
unnecessary complexity. We will discuss findings in relation to the
original research question and how they fit within the conceptual
model developed in the Background section. We will analyse and
discuss findings specific to any geographical settings or contexts,
such as settings also receiving MDA for other co-endemic diseases,
poverty levels, and programme design (such as form of delivery,
drug regimen, and rounds of MDA received at the time of the study),
as well as diFerences in perceptions between male and female
community members.
Finally, we will update the conceptual model to reflect the new
understanding, and we will discuss any developments.
We will use Atlas.ti soJware to manage the data.
Assessing our confidence in review findings
Two review authors (MT and RT) will use the GRADE-CERQual
(Confidence in the Evidence from Reviews of Qualitative Research)
approach to assess our confidence in each finding (Lewin 2018).
CERQual assesses confidence in the evidence based on the
following four key components.
• Methodological limitations of included studies: the extent to
which there are concerns about the design or conduct of the
primary studies that contributed evidence to an individual
review finding.
• Coherence of the review finding: how clear and cogent the fit is
between data from the primary studies and a review finding that
synthesizes those data. By 'cogent', we mean well supported or
compelling.
• Adequacy of the data contributing to a review finding: the
degree of richness and the quantity of data supporting a review
finding.
• Relevance of included studies to the review question: how
the body of evidence from the primary studies supports a
review finding. This information is applicable to the context
(perspective or population, phenomenon of interest, setting)
specified in the review question.
AJer assessing each of the four components, we will make a
judgement about our overall confidence in the evidence supporting
the review finding. We will judge confidence as high, moderate, low,
or very low. We will base the final assessment on consensus among
the review authors. All findings will start as high confidence and
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then will be downgraded if there are important concerns regarding
any of the CERQual components.
Sensitivity analysis
As we intend to include all studies in the synthesis, regardless
of quality assessment, we will conduct a sensitivity analysis to
ascertain how removing studies assessed as 'low quality' will aFect
content and confidence in findings.
'Summary of qualitative findings' table and evidence
profile
We will present summaries of findings and our assessments
of confidence in these findings in the 'Summary of qualitative
findings' table. We will present detailed descriptions of our
confidence assessment in an evidence profile.
Review author reflexivity
In qualitative research, we appreciate that the background and
position of researchers will shape interpretation of results, and thus
team positionality at the outset, through the process of analysis
and synthesis. We state these broad positionality statements at
the outset here. PG was the clinician organizing the delivery of
MDA for LF as part of a research project in the Maprik Area of the
West Sepik in the 1980s. These populations were heavily diagnosed
with filariasis, and the DEC made people unwell, so he has seen
adverse eFects first-hand. As a public health professional, his
values and principles include believing that health professionals
take account of views of the public on clinical and public health
policies. His research reflects these values. MT, RT, and SO have
no personal experience regarding MDA programmes and hold
diFering perspectives on their value. RT is working on a project
on human rights and guideline development and is sensitive
to policies from a human rights perspective. SO is ambivalent
about MDA programmes and views them from the standpoint of
families rather than practitioners. The work will build on MT’s
thesis, which highlighted several consumer concerns about the
programme. Before she conducted this research, MT's views on
MDA were influenced by her academic tuition to date, which
involves a provider-centred rhetoric that MDA is a highly eFective
and appropriate solution.
Analysis will be conducted by two primary analysts (MT and
RT), who will additionally provide feedback on their findings
and interpretations to the whole research team. This will involve
regular meetings with PG and occasional meetings with SO. As
diFerent researchers will approach the analysis from diFerent
perspectives, this collaborative eFort should produce a richer, more
nuanced understanding of a complex situation while generating
opportunities to identify and contest any assumptions or beliefs
held by individual review authors. To further increase reflexivity in
our research design, we will aim to explore and explain any findings
that appear to contradict our understanding of the situation.
Primary analysts will keep memo notes during the initial stages
of analysis to provide a transparent account of the interpretation
process and the development of themes.
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Form of delivery Definition Approach
Type I "Programs in which individuals or groups/organizations indigenous to the community to




Type II "Programs in which individuals or community groups/organizations groups/ organiza-




Type III "Programs in which individuals or community-based community based organizations
(CBOs) pursue external fiscal support or funding"
Bottom-up
Bottom up
Type IV "Programs in which individuals or CBOs indigenous to the target community initiate and
recruit external technical and fiscal support"
Bottom-up
Bottom up
Type V "Programs which are initiated by external change agencies (public or private organiza-
tion, university, a corporation, a foundation or some other philanthropic group, and so
on) within a target community, but [are done] does it without any input from individual
residents or organizations of that community, except as program recipients"
Top-down
Top down
Type VI "Programs which are planned and initiated by external change agencies, and community
members are eventually invited to participate on community advisory committees, or as
lower-level lower level project staF such as 'community "community outreach workers',
workers", or as volunteers"
Top-down
Top down
Type VII "Programs which are planned and implemented as an equitable partnership by CBOs and
an external change agent or technical organization"
Collaborative
Table 1.   Types of delivery in MDA programmes 
Abbreviations: MDA: mass drug administration.
Amended from Whitehead 2002.
 
 
Author Aims Methods Inclusion criteria Number
of studies
Babu 2014 “To systematically review pub-
lished studies on the coverage
of and compliance with MDA
under the Programme for the
Elimination of Lymphatic Filar-
iasis (PELF) in India”
Quantita-
tive
• Up to 2013
• India
• Quantitative studies and quantitative data that can be
extracted from mixed-methods studies
• “Community based studies that evaluated MDA coverage
and compliance conducted by the health services. Data
were excluded if governmental, nongovernmental or re-
search organisations intervened to improve compliance.
However, papers that reported such studies were consid-





the barriers and facilitators to





tive (n = 3)
• 2000 to 2016
• Sub-Saharan Africa
• Studies that assessed the following outcomes: “(i) treat-
ment coverage/compliance, (ii) program sustainability,
18
Table 2.   Characteristics of review studies 
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Quantita-











(iii) successful implementation referring to perceptions
among implementation stakeholders (both provider and
community) that a given treatment, service, practice, or
innovation is agreeable, palatable, or satisfactory with
their needs, and (iv) community participation, defined as




“To attempt to identify factors
and patterns that are associat-
ed with compliance with MDA












• 2000 to 2012
• Global
• “Studies that: (i) reviewed the literature on compliance
with MDA for LF; (ii) described or assessed factors associ-
ated with compliance with MDA for LF; (iii) analysed, ob-
served, or documented compliance rates with MDA and/
or provided an explanation or discussion of the rates; and




“To rapidly review the existing
qualitative literature to identi-
fy perspectives from the com-
munity and drug distributors.
We focused on factors influ-
encing feasibility of planning
and carrying out campaigns




• 2002 to 2017
• Global
• Qualitative studies and qualitative data that can be ex-
tracted from mixed-methods studies
• Studies that “discussed community and/or drug distribu-
tor perceptions of and experiences with any form of MDA
for LF elimination. Community encompasses people re-
ceiving treatment as well as those around them. A drug
distributor can be anyone distributing medicines”
14
Table 2.   Characteristics of review studies  (Continued)




#1 Search filaria* Field: Title/Abstract
#2 Search "Elephantiasis, Filarial"[Mesh]
#3 Search "Filariasis"[Mesh]
#4 Search lymphedema Field: Title/Abstract
#5 Search lymphoedema Field: Title/Abstract
#6 Search "Wuchereria bancrofti"[Mesh] OR "Brugia malayi"[Mesh]
#7 Search (((((#6) OR #5) OR #4) OR #3) OR #2) OR #1
Table 3.   MEDLINE search strategy 
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#8 Search mass drug administration Field: Title/Abstract
#9 Search "Mass Drug Administration"[Mesh]
#10 Search "mass administration" Field: Title/Abstract
#11 Search "coordinated administration" Field: Title/Abstract
#12 Search "mass treatment " Field: Title/Abstract
#13 Search "mass distribution" Field: Title/Abstract
#14 Search "coordinated distribution" Field: Title/Abstract
#15 Search ((((((#14) OR #13) OR #12) OR #11) OR #10) OR 9) OR #8
#16 Search (#15) AND #7
#17 Search "Qualitative Research"[Mesh]
#18 Search "focus group*" or "grounded theory" or "narrative analys*" or "lived experience*" or "life
experience*" or "theoretical sampl*" or purposive Field: Title/Abstract
#19 Search semi-structured OR semistructured OR "structured categor*" OR "unstructured categor*"
OR "action research" OR (audiorecord* OR tape recorded *or videorecord* OR videotap*) OR (au-
dio OR tape OR video*) OR interview* OR quasi-experiment* OR "case stud*" Field: Title/Abstract
#20 Search "Interviews as Topic"[Mesh] OR "Interview" [Publication Type]
#21 Search "Focus Groups"[Mesh]
#22 Search qualitative or ethno* or emic or etic or phenomenology* or hermeneutic* Field: Title/Ab-
stract
#21 Search "Surveys and Questionnaires"[Mesh]
#22 Search "Self Report"[Mesh]
#23 Search "Anthropology, Cultural"[Mesh]
#24 Search collaborat* or consultat* or experience or involve* or narrative* or opinion* or participat*
or partner* or perspective* or story or stories Field: Title/Abstract
#25 Search (((((((((#24) OR #23) OR #22) OR #21) OR #20) OR #19) OR #18) OR #17
#26 Search (#25) AND #16 Filters: Publication date from 2000/01/01
Table 3.   MEDLINE search strategy  (Continued)
This is the preliminary search strategy for MEDLINE (PubMed). It will be adapted for other electronic databases. All search strategies will
be reported in full in the final version of the review.
 
 
A P P E N D I C E S
Appendix 1. EPPI Centre quality assessment tool
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1. Were steps taken to increase rigour in the sampling? Consider whether: *the sampling strategy
was appropriate to the questions posed in the study (e.g. was the strategy well-reasoned and justi-
fied?); *attempts were made to obtain a diverse sample of the population in question (think about
who might have been excluded; who may have had a different perspective to offer); *character-
istics of the sample critical to the understanding of the study context and findings were present-
ed (i.e. do we know who the participants were in terms of, for example, basic socio-demographics,
characteristics relevant to the context of the study, etc.)
Yes, a fairly thorough attempt
was made. 
Yes, several steps were taken. 
Yes, a few steps were taken. 
No, not at all/not stated/can’t
tell
2. Were steps taken to increase rigour in the data collected? Consider whether: *data collection
tools were piloted/(and if quantitative) validated; *(if qualitative) data collection was comprehen-
sive, flexible and/or sensitive enough to provide a complete and/or vivid and rich description of
people’s perspectives and experiences (e.g. did the researchers spend sufficient time at the site/
with participants? Did they keep ‘following up’? Was more than one method of data collection
used?); * steps were taken to ensure that all participants were able and willing to contribute (e.g.
processes for consent, language barriers, power relations between adults and children/young peo-
ple)
Yes, a fairly thorough attempt
was made. 
Yes, several steps were taken. 
Yes, minimal/few steps were
taken. 
No, not at all/not stated/can’t
tell
3. Were steps taken to increase rigour in the analysis of the data? Consider whether: *data analy-
sis methods were systematic (e.g. was a method described/can a method be discerned?); *diversi-
ty in perspective was explored; *(if qualitative) the analysis was balanced in the extent to which it
was guided by preconceptions or by the data; *the analysis sought to rule out alternative explana-
tions for findings (in qualitative research, this could be done by, for example, searching for negative
cases/exceptions, feeding back preliminary results to participants, asking a colleague to review the
data, or reflexivity; in quantitative research, this may be done by, for example, significance testing)
Yes, a fairly thorough attempt
was made. 
Yes, several steps were taken.
Yes, minimal/few steps were
taken. 
No, not at all/not stated/can’t
tell
4. Were the findings of the study grounded in/supported by the data? Consider whether: *enough
data are presented to show how the authors arrived at their findings; *the data presented fit the in-
terpretation/support claims about patterns in data; *the data presented illuminate/illustrate the
findings; *(for qualitative studies) quotes are numbered or otherwise identified and the reader can




5. Please rate the findings of the study in terms of their breadth and depth. Consider whether (NB: it
may be helpful to consider ‘breadth’ as the extent of description and ‘depth’ as the extent to which
data have been transformed/analysed); *a range of issues are covered; *the perspectives of partic-
ipants are fully explored in terms of breadth (contrast of two or more perspectives) and depth (in-
sight into a single perspective); *richness and complexity have been portrayed (e.g. variation ex-
plained, meanings illuminated); *there has been theoretical/conceptual development
Limited breadth or depth.
Good/fair breadth but very lit-
tle depth. 
Good/fair depth but very little
breadth. 
Good/fair breadth and depth
6. To what extent does the study privilege the perspectives and experiences of children? Consider
*whether there was a balance between open-ended and fixed response options; *whether children
were involved in designing the research; *whether there was a balance between the use of an a pri-
ori coding framework and induction in the analysis; *the position of the researchers (did they con-
sider it important to listen to the perspectives of children?); *whether steps were taken to assure





7. Overall, what weight would you assign to this study in terms of the reliability/trustworthiness of




8. What weight would you assign to this study in terms of the usefulness of its findings for this re-
view? Guidance: think (mainly) about the answers you have given to questions 5 and 6 above, and
consider *the match between the study aims and findings and the aims and purpose of the synthe-
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